S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:TRDA

Entrada Therapeutics (TRDA) Stock Forecast, Price & News

$15.80
-0.38 (-2.35%)
(As of 09/29/2023 ET)
Compare
Today's Range
$15.56
$16.41
50-Day Range
$13.61
$17.37
52-Week Range
$9.32
$24.38
Volume
30,692 shs
Average Volume
68,952 shs
Market Capitalization
$524.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.50

Entrada Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
37.3% Upside
$21.50 Price Target
Short Interest
Bearish
8.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Entrada Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$505,297 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.07) to ($2.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

879th out of 972 stocks

Pharmaceutical Preparations Industry

412th out of 451 stocks


TRDA stock logo

About Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

TRDA Price History

TRDA Stock News Headlines

Entrada Therapeutics (NASDAQ:TRDA) Rating Reiterated by HC Wainwright
Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
Entrada Therapeutics Inc.
Seven millionaires secretly enable market shock?
A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.
Entrada Therapeutics: Early Stage But Interesting
8-K: Entrada Therapeutics, Inc.
See More Headlines
Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRDA Company Calendar

Last Earnings
8/08/2023
Today
9/29/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRDA
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+32.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-94,620,000.00
Pretax Margin
-149.60%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.77 per share

Miscellaneous

Free Float
30,681,000
Market Cap
$537.18 million
Optionable
Not Optionable
Beta
-0.32
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dipal Doshi (Age 47)
    Pres, CEO & Director
    Comp: $902.08k
  • Mr. Nathan J. Dowden (Age 52)
    Chief Operating Officer
    Comp: $654.6k
  • Dr. Natarajan Sethuraman Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $654.6k
  • Mr. Kory James Wentworth CPA (Age 43)
    CFO & Treasurer
  • Dr. Jared Cohen J.D.
    Ph.D., Gen. Counsel
  • Ms. Kerry Robert M.S.
    Sr. VP of People
  • Dr. Nerissa C. Kreher M.B.A. (Age 50)
    M.D., M.S., Chief Medical Officer
  • Ms. Karla MacDonald
    Chief Corp. Affairs Officer













TRDA Stock - Frequently Asked Questions

Should I buy or sell Entrada Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TRDA shares.
View TRDA analyst ratings
or view top-rated stocks.

What is Entrada Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12 month price objectives for Entrada Therapeutics' stock. Their TRDA share price forecasts range from $18.00 to $25.00. On average, they expect the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for TRDA
or view top-rated stocks among Wall Street analysts.

How have TRDA shares performed in 2023?

Entrada Therapeutics' stock was trading at $13.52 at the beginning of 2023. Since then, TRDA stock has increased by 19.7% and is now trading at $16.18.
View the best growth stocks for 2023 here
.

When is Entrada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our TRDA earnings forecast
.

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.35. The company had revenue of $18.17 million for the quarter, compared to the consensus estimate of $19.56 million.

When did Entrada Therapeutics IPO?

(TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.

What is Entrada Therapeutics' stock symbol?

Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA."

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entrada Therapeutics' stock price today?

One share of TRDA stock can currently be purchased for approximately $16.18.

How much money does Entrada Therapeutics make?

Entrada Therapeutics (NASDAQ:TRDA) has a market capitalization of $537.18 million. The company earns $-94,620,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How many employees does Entrada Therapeutics have?

The company employs 131 workers across the globe.

How can I contact Entrada Therapeutics?

The official website for the company is www.entradatx.com. The company can be reached via phone at 857-520-9158 or via email at investors@entradatx.com.

This page (NASDAQ:TRDA) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -